AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02485769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Tablet (Modified Release)
Study NCT02485769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet (Modified Release)
Study NCT03033706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse pressure variation guided fluid therapy
Description: Pulse pressure variation obtained from invasive blood pressure waveform
Study NCT03033706 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional fluid therapy
Description: 4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
Study NCT03033706 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Brain tumor excision
Description: Brain tumor excision under general anesthesia
Study NCT03033706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain tumor excision
Description: Brain tumor excision under general anesthesia
Study NCT03088397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: One sheet of postpartum contraceptive information arranged in a grid.
Study NCT03088397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Website
Description: Patient directed to website with information on various contraceptive methods.
Study NCT03088397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared- Decision Making Counseling
Description: Counseling using principles of shared-decision making
Study NCT03088397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared- Decision Making Counseling
Description: Counseling using principles of shared-decision making
Study NCT02744456 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Losartan
Description: An angiotensin II receptor antagonist drug used mainly to treat high blood pressure.
Study NCT02744456 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Description: A calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension.
Study NCT02744456 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide
Description: A diuretic medication often used to treat high blood pressure and swelling due to fluid build up.
Study NCT03334175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: 1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
Study NCT03421457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus-preserving laparoscopic lateral suspension with mesh
Description: V-shaped 2cm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3-4 cm superoposterior to the anterosuperior iliac spine.A grasper is introduced retroperitoneally through the sub-peritoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Round ligament is lifted upward and tunnel is practiced horizontally.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba-Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level.
Study NCT03421457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus-preserving laparoscopic sacrocervicopexy with mesh
Description: The peritoneum over the sacral promontory is incised until the anterior longitudinal ligament is reached and ureters are identified. Peritoneal relaxing incision is made medial to the right ureter, down into the pelvis, posterior to the cervix and rectovaginal fascia, laterally to the rectum. The arm of the mesh is sutured to the posterior cervix by 2.0 prolene and fixated to the sacral promontory by either Tacker (Covidien) and/or 2.0 prolene as tension-free. Complete peritonisation of the mesh is performed.
Study NCT02557997 — intervention group
Intervention type: OTHER
Intervention: Blood tube bottom analyses
Study NCT00549055 — intervention group
Intervention type: DRUG
Intervention: Macugen
Description: Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)
Study NCT02967445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arabin Pessary
Description: Arabin silicon pessary
Study NCT02967445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cerclage
Study NCT03925155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZ scrub vaginal chlorhexidine 4% solution
Description: Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution
Study NCT03925155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% provodine-iodine vaginal preparation
Description: Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution
Study NCT03772223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
Study NCT01042860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein
Description: Lutein supplement, 10 mg daily
Study NCT01042860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02181829 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Lung IMRT
Description: External beam radiation therapy will be administered on an outpatient basis, once daily (except weekends and holidays) for approximately two weeks. Patients will undergo a simulation prior to initiation of radiation. Once an IMRT plan is generated which meets all dose constraints specified patients will be treated with 6MV photons for 10 treatments.
Study NCT03261622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral nerve stimulation at different stimulation amplitudes
Description: Exploring the effect of different stimulation amplitude in a randomized study
Study NCT03261622 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sacral nerve stimulation at different stimulation amplitudes
Description: Exploring the effect of different stimulation amplitude in a randomized study
Study NCT03772223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Budesonide metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).
Study NCT03772223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
Study NCT02464384 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venipuncture, ultrasound, MRI, x-ray
Description: Collection of blood samples and ultrasound / MRI and x-ray examination
Study NCT01914380 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Patients will be followed-up for 24 months
Study NCT01251809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oncaspar
Description: 2000 U/m2 BSA, single infusion
Study NCT01251809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rASNase
Description: 500, 1000 or 1500 U/m2 BSA single infusion
Study NCT03572985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement
Study NCT03572985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Car-following test
Description: Driving with simulator program for DCV measurement
Study NCT00085735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00085735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT00085735 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Craniospinal Irradiation
Description: Undergo craniospinal Irradiation
Study NCT00085735 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Craniospinal Irradiation
Description: Undergo craniospinal Irradiation
Study NCT03572985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement
Study NCT02874807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Study NCT02874807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04720482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Somatosensory Evoked Potentials
Description: SSEP performed bilaterally with stimulation of the median nerve
Study NCT04720482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Automated Pupillometry
Description: PLR quantified as NPi using a handheld automated pupillometer
Study NCT04515693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 Minutes Walking Test
Description: A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.
Study NCT01864538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: 480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
Study NCT04543994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remestemcel-L
Description: An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
Study NCT04543994 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT00934570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and standard exercise
Description: Metformin 1500 mg daily for 2 years
Study NCT00934570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Intensive exercise
Description: Metformin 1500 mg daily for 2 years
Study NCT00934570 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Standard exercise
Description: Standard exercise
Study NCT00934570 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive exercise
Description: Placebo Intensive exercise
Study NCT02562560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Study NCT02562560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral imaging (MRI, PET-FDG)
Study NCT03586128 — intervention group
Intervention type: DRUG
Intervention: PrEP
Description: PrEP will be introduced into clinics according to Uganda national guidelines using a stepped wedge design. Uganda guidelines recommend any tenofovir disoproxil fumarate (TDF) containing medication be used for PrEP; this includes emtricitabine (FTC)/TDF, lamivudine (3TC)/TDF or TDF alone.
Study NCT03586128 — intervention group
Intervention type: DRUG
Intervention: ART
Description: ART medication will be provided according to Uganda national guidelines for persons living with HIV.
Study NCT04509349 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Altering Current Stimulation
Description: The participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage.
Study NCT04509349 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial Altering Current Stimulation
Description: The participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage.
Study NCT04509349 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tACS
Description: 2 saline sponge electrodes will be attached to the upper arm contralateral to hand attached to the accelerometer.
Study NCT04509349 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tACS
Description: 2 saline sponge electrodes will be attached to the upper arm contralateral to hand attached to the accelerometer.
Study NCT00865540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone acetate 1%
Description: 1 drop every 8h two days before surgery
Study NCT00865540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 0.4%
Description: 1 drop every 8h two days before surgery
Study NCT00865540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nepafenac 0.1%
Description: 1 drop every 8h two days before surgery
Study NCT00865540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylcellulose 0.5%
Description: 1 drop every 8h two days before surgery
Study NCT01882608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Telemetry (MHT)
Description: Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
Study NCT03383016 — intervention group
Intervention type: OTHER
Intervention: Lifestyle questionnaires
Study NCT03383016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prostate Biopsy
Description: Possible follow-up by an urologist at 1 year and 2 years after recruitment. After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
Study NCT05390619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 50% dose of photodynamic therapy
Description: Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 50% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
Study NCT05390619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 70% dose of photodynamic therapy
Description: Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 70% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
Study NCT03848182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered on days 1, 8, 15 every 28 days
Study NCT03875898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 150 g bread fortified (15 g mix fibre)
Description: Daily consumption of 150g of a bread fortified in fibre mix (15g) during eight weeks.
Study NCT03875898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 150 g unfortified bread
Description: Daily consumption of 150g of an usual bread in fibre-unfortified bread during eight weeks
Study NCT00837109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veteran Nightmare Treatment
Description: Veteran Nightmare Treatment Using Imagery Rescripting
Study NCT00837109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Treatment-as-usual in the Trauma Recovery Program (that does not specifically target PTSD symptoms)
Study NCT00429403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose.
Study NCT03976037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.
Study NCT02466152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 Topical Cream
Description: GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram \[mg/g\]) and 1.0% (10 mg/g)
Study NCT01499420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL112 (reconstituted high density lipoprotein)
Description: Single escalating intravenous doses of CSL112
Study NCT01499420 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous doses of normal saline (0.9%)
Study NCT04570735 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI
Study NCT03958162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung biopsy
Description: transbronchial lung cryobiopsy
Study NCT02554123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E ointment application
Description: Vitamin E ointment application. Every 12 hours during 7 days.
Study NCT02554123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline ointment application
Description: Vaseline ointment application. Every 12 hours during 7 days.
Study NCT02486198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)
Study NCT02486198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM
Description: 1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)
Study NCT02486198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin-based chemotherapy
Description: chemotherapy contains oxaliplatin
Study NCT02486198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxaliplatin-based chemotherapy
Description: chemotherapy contains oxaliplatin
Study NCT02707367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Roadmap (RR) Wave 1
Description: A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library.
Study NCT02707367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Roadmap (RR) Wave 2
Description: A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library.
Study NCT04245007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Doing fasting 2 days a week within 8 weeks